Entrada Therapeutics 2024年第四季度GAAP每股收益$0.03超过预期$(0.67),销售额$37.40M超过预期$13.12M

财报速递2025-02-27
Entrada Therapeutics (NASDAQ:TRDA) 公布季度每股收益为$0.03,超过分析师一致预期$(0.67),超出104.48%。与去年同期$(0.29)的亏损相比,这一增长为110.34%。公司季度销售额为$37.40百万,超过分析师一致预期的$13.12百万,超出185.04%。与去年同期$41.85百万的销售额相比,减少了10.63%。

以上内容来自Benzinga Earnings专栏,原文如下:

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.67) by 104.48 percent. This is a 110.34 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.12 million by 185.04 percent. This is a 10.63 percent decrease over sales of $41.85 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法